CALC

CalciMedica, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001534133 Biotech & Drug Discovery

$1.30 +0.07 (+5.69%)

Oct 26 4:00 PM ET · prev $1.23

Market cap

$7.9M

Nano cap

Consensus

Buy

78% Buy or better · 9 analysts

Median target

$30.00

+2208% · range $9.00–75.00

Next earnings

Nov 10

in 15 days · EPS est. −$1.27

1 year

−91.4%

from $15.15 · Oct 27

30 days

−22.6%

from $1.68

52-week range

$1.02–33.70

−96% from high · low Oct 19

Avg volume 20D

74.0K

Oct 8 spike 221.3K

Short interest

86.4K

≈1.3% of shares · −22.6%

Days to cover

1.5

at average volume

Insider net

+$200.0K

1 buyer · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BEARISH 6 reports · 90 days

Balance 5 bearish · 0 bullish · 1 neutral oldest → newest, height = score

Avg score

·High conf. 6/6 ·Next Earnings date, Nov 10, 2026

Strongest BEARISH CFO Stephen Bardin resigned effective after the Q3 2026 10-Q filing to pursue another opportunity, with no…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Jun 25 1 insider buy $200.0K at $0.8033
X Jul 31 Short interest falls 47.6% to 503.1K
R Aug 11 CalciMedica reported Q2 2026 financial results with a net loss of $7…
X Aug 14 Short interest falls 35.8% to 323.2K
A Aug 20 Guggenheim initiates
E Aug 28 Trading halt: Trading Halt: CALC — T1 (News Pending)
X Aug 31 Short interest falls 60.5% to 127.7K
R Sep 2 CalciMedica resolved its Nasdaq MVLS deficiency by qualifying under…

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $200.0K. No open-market sales.
InstitutionsMIXED

Q2 2026: 2 added (0 new), 2 trimmed or exited.
AnalystsBULLISH

7 of 9 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$1.717 → −$1.275 over 90 days. 1 up, 0 down in 30 days.
Short sellersCOVERING

Short interest −22.6% to 86.4K shares. 1.5 days to cover, ≈1.3% of shares.
TrendDOWNTREND

31% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	TRIM	88,956	$91.6K
SUSQUEHANNA INTERNATIONAL GROUP, LLP	ADD	43,968	$45.3K
Rockefeller Capital Management L.P.	DOUBLED	20,000	$20.6K
SIMPLEX TRADING, LLC	TRIM	4,723	$4.9K
JANE STREET GROUP, LLC	DOUBLED	178,515	$96.4K
RENAISSANCE TECHNOLOGIES LLC	ADD	128,075	$69.2K
Rockefeller Capital Management L.P.	TRIM	5,000	$2.7K
UBS Group AG	NEAR_EXIT	17	$9.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts

Buy 78% rate it Buy or better

Strong Buy3Buy4Hold2Sell0Strong Sell0

12-month targets · 3 analysts

$1.30 $9.00 $30.00 $75.00

Price is below the lowest target. Median implies +2208%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 20, 2026	Guggenheim INITIATE	INITIATE	Buy

Insider ledger

Form 4

$200.0K

bought · 1 insider

sold · 0 insiders

Date	Insider	Type	Value
Oct 1, 2026	Glicklich Alan Director	AWARD	20,000 sh
Oct 1, 2026	Zaytsev Evgeny Director	AWARD	20,000 sh
Oct 1, 2026	Guerard Frederic Director	AWARD	20,000 sh
Oct 1, 2026	WILSON ROBERT N Director	AWARD	20,000 sh
Oct 1, 2026	Shaw Allan Director	AWARD	20,000 sh
Sep 24, 2026	Bardin Stephen Chief Financial Officer	AWARD	190,000 sh
Sep 24, 2026	Leheny A. Rachel CHIEF EXECUTIVE OFFICER	AWARD	360,000 sh
Sep 24, 2026	Stauderman Kenneth A. Chief Scientific Officer	AWARD	180,000 sh

Earnings setup

Estimates

Nov 10

reports in 15 days

−$1.27

EPS estimate, this quarter

+26%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$1.717

90d

−$1.683

60d

−$1.975

30d

−$1.975

−$1.275

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$1.27	-$1.80–-$0.75	+35.4%	$0.00
Next Q	-$1.05	-$1.25–-$0.85	+46.2%	$0.00
Current FY	-$3.02	-$3.95–-$2.45	+20.1%	$0.00
Next FY	-$5.30	-$10.60–-$2.15	+7.4%	$0.00